0001062993-24-001164.txt : 20240122 0001062993-24-001164.hdr.sgml : 20240122 20240122185920 ACCESSION NUMBER: 0001062993-24-001164 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240119 FILED AS OF DATE: 20240122 DATE AS OF CHANGE: 20240122 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McWherter Charles CENTRAL INDEX KEY: 0001588862 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36500 FILM NUMBER: 24550142 MAIL ADDRESS: STREET 1: C/O CYMABAY THERAPEUTICS, INC. STREET 2: 7575 GATEWAY BLVD., SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CymaBay Therapeutics, Inc. CENTRAL INDEX KEY: 0001042074 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943103561 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7575 GATEWAY BOULEVARD STREET 2: SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-293-8800 MAIL ADDRESS: STREET 1: 7575 GATEWAY BOULEVARD STREET 2: SUITE 110 CITY: NEWARK STATE: CA ZIP: 94560 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX, INC. DATE OF NAME CHANGE: 20090721 FORMER COMPANY: FORMER CONFORMED NAME: METABOLEX INC DATE OF NAME CHANGE: 19970710 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2024-01-19 0001042074 CymaBay Therapeutics, Inc. CBAY 0001588862 McWherter Charles C/O CYMABAY THERAPEUTICS, INC. 7575 GATEWAY BLVD., SUITE 110 NEWARK CA 94560 0 1 0 0 President of R&D 1 Common Stock 2024-01-19 4 M 0 2250 1.06 A 17250 D Common Stock 2024-01-19 4 S 0 2250 23.6721 D 15000 D Common Stock 2024-01-19 4 M 0 2778 1.72 A 17778 D Common Stock 2024-01-19 4 S 0 2778 23.6641 D 15000 D Common Stock 2024-01-19 4 M 0 1916 1.82 A 16916 D Common Stock 2024-01-19 4 S 0 1916 23.6641 D 15000 D Common Stock 2024-01-19 4 M 0 8334 10.00 A 23334 D Common Stock 2024-01-19 4 S 0 8334 23.6760 D 15000 D Common Stock 2024-01-19 4 M 0 3125 11.69 A 18125 D Common Stock 2024-01-19 4 S 0 3125 23.6760 D 15000 D Employee Stock Option (right to buy) 1.06 2024-01-19 4 M 0 2250 0 D 2026-01-25 Common Stock 2250 51750 D Employee Stock Option (right to buy) 1.72 2024-01-19 4 M 0 2778 0 D 2027-01-18 Common Stock 2778 97222 D Employee Stock Option (right to buy) 1.82 2024-01-19 4 M 0 1916 0 D 2026-07-24 Common Stock 1916 44084 D Employee Stock Option (right to buy) 10.00 2024-01-19 4 M 0 8334 0 D 2025-01-06 Common Stock 8334 91666 D Employee Stock Option (right to buy) 11.69 2024-01-19 4 M 0 3125 0 D 2028-01-23 Common Stock 3125 146875 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 29, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.48 to $24.20, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.45 to $24.305, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vested as to 1/4 of the underlying shares on the first anniversary of the grant date and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter. The option vested as to 1/2 of the underlying shares on December 30, 2016 and the remaining 1/2 of the underlying shares vested on January 4, 2017. The option vested as to 1/4 of the underlying shares on January 1, 2019 and the remaining 3/4 of the underlying shares vested ratably on a monthly basis over the 36 months thereafter. /s/ Paul Quinlan, as attorney-in-fact for Charles McWherter 2024-01-22